Anabolic Steroids/Hormones
Anavar
Also called Oxandrolone · Var
Anavar draws lifters who want strength, fuller muscles and more definition while staying relatively lean. Some enjoy the pumps; others find cramps or stomach trouble interfere with training. Its mild reputation can hide cholesterol, liver and hormone effects, including potentially lasting voice changes in women.
Dosage & duration
Oral oxandrolone: separately attributed nonmedical examples, not current bodybuilding prescriptions.
Reported nonmedical proposal · men
Reported use · unapproved regimen- Dose
- 40–50 mg total per day
- How often
- Daily by mouth; within-day split not stated
- How long
- 6 weeks proposed
One public plan, not confirmed completed use or a safe-course standard. Its stated goal was lean mass after dieting.
One woman’s self-report
Reported use · unapproved regimen- Dose
- 5 mg/day reported as 2.5 mg morning and evening
- How often
- Twice daily by mouth
- How long
- 5 weeks reported
The poster also described a brief 10 mg/day trial, voice cracking and uncertain tablet contents. This is not evidence that 5 mg is safe or that the reported effects were caused by verified oxandrolone.
Daily totals are not per-tablet amounts. Men’s examples are not converted into a women’s dose by taking a fraction; no reported course establishes safety or a recovery schedule.
More quick facts
- Why lifters choose it
- Strength, fullness and definition
- Practical trade-off
- A pump can become a cramp
Anavar at a glance
The desired pump and the practical trade-off
What users seek
-
Strength and definition
People seek fuller muscles and better lifts while staying relatively lean.
What users report
-
Pumps can limit exercise
Some enjoy the workouts; others describe cramps, tight calves or stomach trouble.
Voice changes can last In women, early voice or other masculinizing changes need prompt clinical attention; small reported amounts do not establish a safe threshold.
Why people seek Anavar
In lifting discussions, the appeal is looking fuller and more defined while improving strength, without chasing a large jump in scale weight. Taking tablets also seems simpler than injecting. Some describe enjoyable pumps and stamina; others report cramps, stomach trouble or fatigue that make training less enjoyable.
Is it a cutting drug or a muscle builder?
Those labels describe goals, not separate effects. Trials in older adults found changes in lean tissue and fat, but the results cannot be treated as a forecast for younger trained users. In older women, better body composition did not add strength or function beyond training alone. Comparing Anavar with Winstrol comes down to reported appearance and tolerability; personal preferences do not establish a winner.
What the mild reputation leaves out
Oxandrolone can adversely affect cholesterol, injure the liver and suppress natural testosterone production. Avoiding injections does not remove those effects. Some experience reports describe feeling and looking good alongside concerning blood results.
For women, a new hoarse or deepening voice is a reason to stop and seek prompt clinical assessment, rather than finish a course. Some masculinizing changes can persist despite stopping. Pregnancy is a contraindication, and the interaction with warfarin can increase bleeding risk.
Do the gains stay?
No fixed amount can be promised. In the older-men trial, lean mass and strength were no longer significantly above baseline twelve weeks after treatment ended, though some fat reduction persisted. That is one population’s result, not a rule for every lifter. An on-course pump or personal best is not the same thing as a permanent change.
Reading dose reports and approval claims
The dose cards keep men’s and women’s public examples separate; neither establishes a safe range or course length. Workout-timing reports also do not prove that chasing a plotted peak improves results.
FDA withdrew Oxandrin and several generic approvals in 2023 and clarified the generic withdrawals in October 2026. Historical labels remain useful for warnings; they do not show that an Anavar product sold today is FDA-approved. The plot uses relative units and does not verify tablet contents or predict blood levels.
Model details: Anavar · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Tmax oral-tablet mean verified; 9.5 h stays a conservative label-era assumption, not derived fromMCT 6.7 h.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 9.5 hours
- Absorption half-life assumed
- 0.314692 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 1.6 h source-scoped peak time; absorption half-life 0.31469202358666837 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Exactmean dose/per-person dose-to-table mapping is absent; a cohort mean Cmax cannot be confidently assigned to 10 mg.
- A possible approximate reference is 8.45 mg (=0.1 mg/kg ×median 84.5 kg), but this is not a measuredmean dose and should require an explicitly accepted additional assumption.
- The 6.7 h mean belongs tobuccal MCT; tablets described as similar without a numericaltable half.
- Use relative output rather than silently choose a reference dose; fixed-dose FDA table remains a specific follow-up.
- Linakis 2020 oxandrolone oral/buccal MCT Table 4
6 fasted men; oral 67.6 ng/mL, Tmax 1.6 h, 7.5–10 mg doses.62.5% is buccal MCT relative tooral; 6.7 h reported forMCT.
- FDA ANDA 076897 original approval package
A fixed-dose tablet bioequivalence lead exists but was not successfully retrieved for table verification.
anavar-relative-timing-2026-10 · version 1
Safety and interaction notes Read the limitations and discuss clinical questions with a professional
- Aromatizes
- No
- DHT derivative
- Yes
Common questions
Is Anavar a fat burner?
Some older-adult trials found reduced fat mass, but they do not predict a cutting result or spot fat loss for a younger trained user.
Can women avoid voice changes by using a small amount?
No reliable safe threshold is established by reported examples. Some changes can persist even after stopping; early voice changes need prompt clinical attention.
Does taking Anavar without injections avoid hormone suppression?
No. Oxandrolone can suppress the signals involved in natural testosterone production regardless of taking it by mouth.
Does a bigger pump mean more muscle growth?
Not by itself. A pump is a short-term experience; painful cramps or tightness can also interfere with training.
Is Anavar the same as Anadrol?
No. Anavar commonly refers to oxandrolone; Anadrol refers to oxymetholone. The drugs and amounts are not interchangeable.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-10, 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why lifters choose it
- People seek these effects while dieting or comparing Anavar with Winstrol.
- Practical trade-off
- Some users describe great workouts; others find tight calves, back pumps or stomach trouble limit exercise.
- Women’s concern
- Small reported amounts do not establish a safe threshold. Early voice or other masculinizing changes need prompt clinical attention.
- 1. Historical oxandrolone tablet label — warnings checked October 2026
Official text read: liver/lipid effects, suppressed testosterone release, potentially irreversible virilization, pregnancy contraindication and warfarin interaction. Historical label, not evidence of current approval.
- 2. Schroeder et al. — oxandrolone effects and follow-up in older men
Original abstract rechecked via Europe PMC. Thirty-two men aged 60–87; muscle/strength/body-composition changes during treatment, increased body water; lean-mass and strength increments not different from baseline twelve weeks after stopping. Not a younger-athlete prediction.
- 3. Mavros et al. 2015 — oxandrolone and training in older women
Original abstract rechecked via Europe PMC. Twenty-nine sedentary older women; body-composition changes without additional strength or functional gain beyond training alone. Not a safe-dose trial for younger women.
- 4. FDA — Oxandrin withdrawal determination and 2026 generic correction
Full official correction read; published October 7, 2026. References 2023 withdrawal, explicitly extends safety/effectiveness determination to listed generic products; not restored approval. September 2023 notice also read.
- 5. Linakis 2020 oxandrolone oral/buccal MCT Table 4
6 fasted men; oral 67.6 ng/mL, Tmax 1.6 h, 7.5–10 mg doses.62.5% is buccal MCT relative tooral; 6.7 h reported forMCT.
- 6. FDA ANDA 076897 original approval package
A fixed-dose tablet bioequivalence lead exists but was not successfully retrieved for table verification.
- 7. Schroeder et al. 2004 — oxandrolone effects and durability in older men
Original abstract checked: 32 men aged 60–87; 20 mg/day for 12 weeks. Lean mass, muscle area and strength increased, with less fat; total body water also increased. Measured lean body mass and strength were no longer statistically significantly above baseline 12 weeks after stopping; off-treatment assessment did not remeasure MRI muscle area. Not a prediction for young trained users.
- 8. Schroeder et al. 2005 — six-week findings in the older-men trial
Same 32-man research program, not an independent replication. 10 mg twice daily for 12 weeks; six-week muscle/strength changes did not improve walking speed or leg power. Used for timing and daily-versus-preworkout context.
- 9. Mavros et al. 2015 — oxandrolone with resistance training in older women
Original abstract checked: 29 sedentary women, mean age about 75; 10 mg/day with training for 12 weeks. Body composition improved beyond training alone, but strength, power and functional gains did not differ between groups. Not a safe-dose study for younger women.
- 10. Historical oxandrolone tablet label — DailyMed
Historical US medical-label context only. Adults: 2.5–20 mg/day in 2–4 divided doses; a 2–4-week course usually adequate, repeated if clinically indicated. Also supports liver/lipid warnings, suppression, potentially irreversible virilization and warfarin interaction. The online label is not evidence of current FDA approval.
- 11. FDA September 2023 — Oxandrin safety/effectiveness withdrawal determination
Official full text checked. Records June 28, 2023 withdrawal of Oxandrin approval and the adverse benefit-risk determination for its labeled uses. Not a claim about every country’s laws.
- 12. FDA October 7, 2026 — correction explicitly covering generic oxandrolone products
Official full text checked; publication date 2026-10-07. Clarifies that referenced generic ANDAs were also withdrawn for safety or effectiveness and are to be removed from the Orange Book. This is a correction to the 2023 notice, not restored approval.
- 13. Mullen et al. 2020 — published compilation of online AAS reports
Table 1 explicitly uses online user reports and supplier marketing, not a dosing trial or representative prescribing survey. Oxandrolone row: oral, men 50–80 mg/day, women 10–20 mg/day; it gives no within-day split or course length. Used as attributed published-report context, not a recommended or safe range.
- 14. Linakis et al. 2020 — oxandrolone tablet versus buccal MCT preparation
Abstract and adult Table 4 checked. Mean 62.5% is relative buccal-MCT availability compared with oral tablets, not absolute oral tablet availability. Six adults; large variability.
Keep reading
Related compounds and examples
Related compounds
Halotestin
Halotestin, or Halo, comes up around powerlifting strength, intense training drive and a harder-looking contest physique rather than large weight gain. Some users like the focus; others describe anger and an experience they would not repeat. Serious liver and other health risks remain even when a workout feels better.
Anadrol
Anadrol is sought for rapid size, fullness and strength, and is often compared with Dianabol. The practical catch is that some users report feeling tired or losing their appetite while trying to gain weight. A fast scale increase is not all new muscle, and the liver, cholesterol and fluid-retention risks still matter.
Dianabol
Dianabol attracts lifters who want fast strength gains and a fuller, bigger look. Users also describe a feel-good effect, but bloating and painful back pumps can spoil the appeal. Rapid scale gain is not all lasting muscle; blood-pressure and liver risks matter even when training feels great.